An observational study in Low-gradient Aortic Stenosis and Aortic Stenosis, sponsored by National Institute of Cardiology, Warsaw, Poland. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-02.
Sponsored by National Institute of Cardiology, Warsaw, Poland · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Aortic Valve Stenosis with a site in Poland — 10 open to participants now, 11 under way, 1 of them phase 3. Aortic Valve Stenosis · Poland.
Among the 30 studies in Aortic Valve Stenosis with a site in Poland, this one is the 7th largest by planned enrollment of the 14 observational ones that give a count, is one of 4 that started in 2025, is one of 14 observational ones, reaches primary completion later than 7 of the 10 other live ones, and was the 29th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →10 of the 30 studies in Aortic Valve Stenosis with a site in Poland are open now. Recruiting first, the newest first:
Ceric Sàrl · Sites in Poland, Austria, Estonia and 11 more countries
Ages 65–75
Novartis Pharmaceuticals · Sites in Poland, United States, Argentina and 20 more countries
Ages 6–11
Thubrikar Aortic Valve, Inc. · Sites in Poland
Ages 70+
Medical University of Warsaw · Sites in Poland
Ages 18+
Queen Silvia Children's Hospital, Gothenburg, Sweden · Sites in Poland, United States, Austria and 5 more countries
Ages 23 wk–31 wk
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2025.
This study's planned enrollment of 300 is above the median of 200 across 437 observational studies indexed under Aortic Valve Stenosis.
Median enrollment 169 across the 16 interventional studies, 250 across the 14 observational. Of the 15 that completed or were terminated, 4 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 30 have an industry lead sponsor. The 10 most frequent:
National Institute of Cardiology, Warsaw, Poland is the lead sponsor of 54 studies on the registry; 12 are open to participants now.
National Institute of Cardiology, Warsaw, Poland has 1 study filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 30 studies in Aortic Valve Stenosis with a site in Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effectiveness of an artificial intelligence (AI) model developed by the investigators for identifying severe low-gradient aortic valve stenosis. Accurate assessment of stenosis severity is crucial for proper qualification for surgical treatment. It is expected that the use of AI will improve diagnostic accuracy and thereby support better clinical outcomes.
Patients with suspected significant low-gradient aortic stenosis will be enrolled. The study is observational and involves no additional risk for participants. Standard imaging studies performed for clinical indications will be additionally analyzed by the AI model, which will classify aortic stenosis as severe or moderate. The model's results will not influence the clinical management of participants but will be compared with physicians' assessments to validate its diagnostic performance.
The study will be conducted in 2025-2026. The findings will provide insights into the usefulness of AI in the diagnosis of severe aortic stenosis and may contribute to the development of advanced clinical decision-support tools.
This study is a prospective multicenter observational validation of an artificial intelligence (AI) model for differentiating severe low-gradient from moderate aortic stenosis using transthoracic echocardiography images. The model, developed and published by the investigators, demonstrated promising diagnostic performance in retrospective data. In the present trial, approximately 300 participants with suspected significant low-gradient aortic stenosis will be enrolled during 2025-2026. Standard imaging studies performed for clinical indications will be analyzed by the AI model, which will classify aortic stenosis as severe or moderate. The AI-derived results will not influence clinical decision-making but will be compared with physicians assessments to evaluate diagnostic accuracy and reproducibility in real-world practice.
The study population will include adult patients (≥18 years) diagnosed in the Echocardiography Laboratory of the National Institute of Cardiology in Warsaw, Department of Valvular Heart Disease. Eligible participants will be those referred for echocardiographic evaluation due to clinical suspicion of significant low-gradient aortic stenosis. Standard-of-care imaging performed for clinical indications will be analyzed. Approximately 300 patients are expected to be enrolled between 2025 and 2026. Patients with previous aortic valve intervention (surgical or transcatheter) or other exclusion criteria will not be included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Approximately 300 patients with suspected significant low-gradient aortic stenosis undergoing standard echocardiographic evaluation between 2025 and 2026. Echocardiographic images will be secondarily analyzed by the AI model to classify stenosis as severe or moderate. The AI results will be compared with physicians assessments. No intervention or modification of clinical care is involved.
Diagnostic Test: AI diagnostic test for severe low-gradient aortic stenosis
All participants will undergo standard transthoracic echocardiography performed for clinical indications. Echocardiographic images will be analyzed both by experienced physicians and by the investigational AI model. Additional diagnostic tests (such as cardiac CT, low-dose dobutamine stress echocardiography or transesophageal echocardiography) may be performed if clinically indicated, according to current guideline recommendations. The AI-derived results will not influence clinical decision-making.
Area Under the Receiver Operating Characteristic Curve (AUC) describing the sensitivity-specificity relationship of the AI model.
AUC will be calculated to assess the ability of the AI model to differentiate between severe low-gradient and moderate aortic stenosis. The analysis will use physician assessment and guideline-based diagnostic criteria as the reference standard. AUC will be reported with 95% confidence intervals.
Time frame: At the time of the nearest Heart Team meeting following the echocardiographic examination (typically within 1 week).
Diagnostic performance of the AI model in clinically relevant subgroups.
Diagnostic performance of the AI model (AUC, sensitivity, specificity) in clinically relevant subgroups, such as patients with atrial fibrillation or subtypes of low-gradient aortic stenosis (classic, paradoxical, normal flow).
Time frame: At the nearest Heart Team meeting following the echocardiographic examination (typically within 1 week).
Plan to share: No
Started Aug 2025 (actual). Primary completion is estimated for Aug 2026, 12 months after the start.
Of 206 non-industry observational studies under Aortic Valve Stenosis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 120. This study's planned 12 months is below that.
Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of Cardiology, Warsaw, Poland